The Latest Breaking News from Natera

Natera Inc (NASDAQ:NTRA) generated Q1 revenues of $194.1 million, up 27.5% Y/Y, beating the consensus of $176.60 million. Product revenues were $190.0 million, an increase of 57.8%. The company processed approximately 489,300 tests, compared to approximately 348,200 tests in Q1 FY21. The gross profit margin compressed to 46.8% from 56.1%, primarily due…

Natera (NASDAQ:NTRA) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Natera will report an earnings per share (EPS) of $-1.48.

Within the last quarter, Natera (NASDAQ:NTRA) has observed the following analyst ratings:

 

Natera (NASDAQ:NTRA) has outperformed the market over the past 5 years by 22.16% on an annualized basis.

A whale with a lot of money to spend has taken a noticeably bearish stance on Natera. Looking at options history for Natera (NASDAQ:NTRA) we detected 39 strange trades.

Natera Inc (NASDAQ: NTRA) shares are trading lower by 31.2% at $37.66 after Hindenburg Research issued a short report on the stock.

Natera Inc (NASDAQ: NTRA) analyst Kyle Mikson of Canaccord Genuity Capital reiterated a Buy rating Wednesday on the genetic testing company  following a Hindenburg Research short 

Over the past 3 months, 4 analysts have published their opinion on Natera (NASDAQ:NTRA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Natera (NASDAQ:NTRA) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Natera missed estimated earnings by 12.98%, reporting an EPS of $-1.48 versus an estimate of $-1.31.

  Over the past three months, shares of Natera (NASDAQ:NTRA) decreased by 34.50%. Before we understand the importance of debt, let us look at how much debt Natera has.